Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc. is a U.S.-based dermatology company focused on developing and commercializing prescription therapies for skin diseases. Its commercial product, YCANTH (VP-102), is a physician-administered topical treatment, and the company also has pipeline programs in common warts and basal cell carcinoma.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueYCANTH (VP-102) is the company's marketed, physician-administered topical therapy.
YCANTH-Rx and pharmacy/wholesaler channels support prescription fulfillment and access.
Development programs for common warts and basal cell carcinoma extend the product platform.
Products
Reported · share of revenue- License and Collaboration Revenue57.0 %
- Products43.0 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
The company sells primarily to pharmaceutical wholesalers and distributors, which then supply pharmacies, clinics, hospitals, and federal healthcare programs. Its commercial focus is on U.S. physicians who treat pediatric dermatology and dermatology patients, especially those managing molluscum contagiosum. Market access teams also work with commercial, Medicaid, and managed Medicaid payers to support reimbursement and adoption.
Buy YCANTH and distribute it onward to pharmacies, clinics, hospitals, and federal healthcare programs.
Prescribe YCANTH for pediatric molluscum contagiosum and are the core clinical audience.
Use YCANTH in dermatology practices and represent a major physician adoption segment.
Help broaden access to treatment beyond specialist dermatology settings.
Commercial, Medicaid, and managed Medicaid plans influence coverage and patient access.
Strategy
Verrica's strategy centers on expanding YCANTH adoption in the U.S. through physician education, consumer awareness, and payer coverage. It is also building a broader cantharidin platform by advancing common-wart and basal-cell-carcinoma programs and by using partnerships to extend reach outside the U.S.
The commercial product is the main source of revenue and brand recognition.
Coverage determines whether physicians and patients can obtain the product efficiently.
Additional approved uses could diversify revenue beyond molluscum contagiosum.
Licensing can extend the platform without building a full international commercial infrastructure.
Geography
Verrica's commercial business is concentrated in the United States, where YCANTH is marketed and shipped. The company also has an out-licensed Japan opportunity through Torii for cantharidin-based products, which extends the platform beyond the U.S. market. Its supply chain includes raw material sourcing from suppliers based in the People's Republic of China, creating upstream geographic exposure.
Risks
The company depends on a single commercial product and on successful reimbursement, physician adoption, and supply continuity. It also faces financing risk, clinical development risk, and competition from established dermatology treatments and future entrants, while raw material sourcing from China adds supply-chain exposure.
- Going-concern and financing riskImpact: CriticalLikelihood: High
The company expects to need additional capital to fund commercialization and R&D.
Exposure: Operations and pipeline funding
- Single-product concentrationImpact: HighLikelihood: High
YCANTH is the only commercial product, so demand changes flow directly into revenue.
Exposure: Revenue and cash flow
- Clinical and regulatory riskImpact: HighLikelihood: High
Pipeline programs need successful trials and FDA approvals before they can contribute revenue.
Exposure - Supply-chain concentrationImpact: HighLikelihood: Medium
Raw cantharidin is sourced directly or indirectly from suppliers in China.
Exposure: API and finished product supply
- Gross-to-net and returns riskImpact: HighLikelihood: Low
Rebates, chargebacks, discounts, and returns can reduce reported net sales.
Exposure - Competitive pressureImpact: MediumLikelihood: High
YCANTH competes with OTC products, procedures, off-label therapies, and future entrants.
Exposure: Dermatology treatment market
Accounting
Judgemental itemsReported net sales depend on estimates for rebates, chargebacks, discounts, and returns.
Impact: Can materially affect quarterly revenue and margins
Some raw materials and components were expensed before approval and later flowed through cost of sales.
Impact: Can distort period-to-period gross margin comparability
Liquidity and financing assumptions affect the presentation of the financial statements.
Impact: Important for assessing balance-sheet and funding risk
Similar listed companies
Publicly listed companies with a comparable business focus.
Soligenix, Inc
SNGX · Pharmaceutical Preparations
Vertex Pharmaceuticals Incorporated
VRTX · Pharmaceutical Preparations
Vertex Pharmaceuticals is a U.S.-based biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases.
Dermata Therapeutics, Inc.
DRMA · Pharmaceutical Preparations
Vera Therapeutics, Inc.
VERA · Pharmaceutical Preparations
Kenvue Inc.
KVUE · Perfumes, Cosmetics & Other Toilet Preparations
Viatris Inc
VTRS · Pharmaceutical Preparations
Last updated: 24/09/2026